Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...
Praxis Precision Medicines said on Thursday its experimental drug for movement disorder helped improve daily functioning in patients in two late-stage trials, sending its shares surging more than ...
Praxis Precision Medicines said on Thursday its experimental drug for a type of movement disorder improved patients' ability to perform daily tasks in two late-stage trials, sending its shares surging ...
Investor's Business Daily on MSN
The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200%
Shares of Praxis Precision MedicinesPRAX skyrocketed more than 200% Thursday, hitting a three-year high, on "groundbreaking" ...
The FDA has slapped a clinical hold on Praxis Precision Medicines’ PRAX-222, a drug aimed at treating early-onset epilepsy and one of the biotech’s three product candidates set to enter clinical-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback